Sun YF, Liu LL, Jiang SS, Zhang XJ, Liu FJ, Zhang WM. Influence of ganglioside combined with methylprednisolone sodium succinate on efficacy and neurological function in patients with acute myelitis. World J Clin Cases 2023; 11(33): 7972-7979 [PMID: 38075571 DOI: 10.12998/wjcc.v11.i33.7972]
Corresponding Author of This Article
Wan-Ming Zhang, MD, Doctor, Department of Special Medicine, Basic Medical College of Qingdao University, No. 821 Ningde Road, Qingdao 266071, Shandong Province, China. zhangwanming0532@126.com
Research Domain of This Article
Clinical Neurology
Article-Type of This Article
Retrospective Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Yu-Fei Sun, Wan-Ming Zhang, Department of Special Medicine, Basic Medical College of Qingdao University, Qingdao 266071, Shandong Province, China
Li-Li Liu, Sha-Sha Jiang, Department of Medical Microbiology, Basic Medical College of Qingdao University, Qingdao 266075, Shandong Province, China
Xian-Juan Zhang, Department of Clinical Laboratory, The Affiliated Hospital of Qingdao University, Qingdao 266000, Shandong Province, China
Feng-Jun Liu, Department of Special Medicine, School of Basic Medicine, Qingdao University, Qingdao 266000, Shandong Province, China
Co-first authors: Yu-Fei Sun and Li-Li Liu.
Author contributions: Sun YF and Liu LL contributed equally to this work and are co-first authors. Sun YF and Liu LL designed the research and wrote the first manuscript; Sun YF, Liu LL, Jiang SS, Zhang XJ, Liu FJ, and Zhang WM contributed to conceiving the research and analyzing data; Sun YF, Liu LL, and Zhang WM conducted the analysis and provided guidance for the research; and all authors reviewed and approved the final manuscript.
Institutional review board statement: This study was approved by the Ethic Committee of Basic Medical College of Qingdao University (Approval No. QDWMkj-2020-012).
Informed consent statement: Patients were not required to give informed consent to the study because the analysis used anonymous clinical data that were obtained after each patient agreed to treatment by written consent.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: All data and materials are available from the corresponding author.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Wan-Ming Zhang, MD, Doctor, Department of Special Medicine, Basic Medical College of Qingdao University, No. 821 Ningde Road, Qingdao 266071, Shandong Province, China. zhangwanming0532@126.com
Received: September 13, 2023 Peer-review started: September 13, 2023 First decision: September 28, 2023 Revised: October 11, 2023 Accepted: October 30, 2023 Article in press: October 30, 2023 Published online: November 26, 2023 Processing time: 72 Days and 0.8 Hours
Abstract
BACKGROUND
Acute myelitis (AM) can lead to sudden sensory, motor and autonomic nervous dysfunction, which negatively affects their daily activities and quality of life, so it is necessary to explore optimization from a therapeutic perspective to curb the progression of the disease.
AIM
To investigate the effect of ganglioside (GM) combined with methylprednisolone sodium succinate (MPSS) on the curative effect and neurological function of patients with AM.
METHODS
First, we selected 108 AM patients visited between September 2019 and September 2022 and grouped them based on treatment modality, with 52 patients receiving gamma globulin (GG) + MPSS and 56 patients receiving GM + MPSS, assigned to the control group (Con) and observation group (Obs), respectively. The therapeutic effect, neurological function (sensory and motor function scores), adverse events (AEs), recovery (time to sphincter function recovery, time to limb muscle strength recovery above grade 2, and time to ambulation), inflammatory factors (IFs) [interleukin (IL)-6, C-reactive protein (CRP), and tumor necrosis factor (TNF)-α] and other data of the two groups were collected for evaluation and comparison.
RESULTS
The Obs had: (1) A significantly higher response rate of treatment than the Con; (2) Higher scores of sensory and motor functions after treatment that were higher than the baseline (before treatment) and higher than the Con levels; (3) Lower incidence rates of skin rash, gastrointestinal discomfort, dyslipidemia, osteoporosis and other AEs; (4) Faster posttreatment recovery of sphincter function, limb muscle strength and ambulation; and (5) Markedly lower posttreatment IL-6, CRP and TNF-α levels than the baseline and the Con levels.
CONCLUSION
From the above, it can be seen that GM + MPSS is highly effective in treating AM, with a favorable safety profile comparable to that of GG + MPSS. It can significantly improve patients’ neurological function, speed up their recovery and inhibit serum IFs.
Core Tip: Acute myelitis (AM) is an autoimmune demyelinating disease in which patients may experience clinical symptoms such as difficult defecation, nerve root pain, lower limb paralysis, low-grade fever, and other symptoms that lead to limitations in daily life. This study mainly verified the clinical advantages of ganglioside + methylprednisolone sodium succinate in the treatment of AM, so as to provide timely and effective treatment for patients with AM and improve the condition and prognosis of patients.
